However, no significant differences were observed in the expression levels of CD3, CD8, or CD28. These results suggest that PD-L1 may be a more effective ICIs target than PD-1 and CTLA4, with CD4+ T-cells playing a key role in the tumor immune response in progressive HNSCC. The gene discussed is CD28; the disease is neoplasm.